JAHA:改善有卒中史的高血压患者结局 可把血压控制在这个范围

2018-02-02 吴星 环球医学

2017年12月,发表在《J Am Heart Assoc》的一项由韩国科学家进行的研究考察了既往卒中的高血压患者中血压与临床结局之间的相关性。

2017年12月,发表在《J Am Heart Assoc》的一项由韩国科学家进行的研究考察了既往卒中高血压患者中血压与临床结局之间的相关性。

背景:本研究考察了平均血压<130/80mmHg是否与经治的既往卒中的高血压患者心血管结局进一步减少相关。

方法和结果:韩国国民健康保险服务健康受检者队列中,确诊为具有卒中和高血压的患者于(N=2320)2003年1月1日~2006年12月31日根据随访健康检查期间记录的平均收缩压(<130、130~<140和≥140mmHg)和舒张压(<80、80~<90和≥90mmHg)进行分组。比较了11年的全因和心血管死亡率。与收缩压≥140mmHg(736人)相比,收缩压为130~<140mmHg(N=793)的患者全因死亡(风险比[HR],0.61;95% 置信区间[CI],0.47~0.79;P<0.001)、心血管死亡(HR,0.39;95% CI,0.25~0.61;P<0.001)和致死性缺血性卒中(HR,0.25;95% CI,0.10~0.63;P=0.003)风险显着更低。收缩压<130mmHg(N=791)与非致死性出血性卒中的较低风险相关。舒张压为80~<90mmHg的患者(N=1100)比舒张压≥90mmHg的患者(N=342)的全因死亡(HR,0.60;95% CI,0.45~0.80;P<0.001)和心血管死亡(HR,0.45;95% CI,0.30~0.70;P<0.001)风险显着更低。舒张压<80mmHg(N=878)与非致死性出血性卒中风险降低和全因死亡和心血管死亡风险进一步降低相关。

结论:血压<130/80mmHg与具有既往卒中的高血压患者的结局改善相关。

原始出处:

Lee CJ, et al. Relation Between Blood Pressure and Clinical Outcome in Hypertensive Subjects With Previous Stroke. J Am Heart Assoc. 2017 Dec 6;6(12). pii: e007102. doi: 10.1161/JAHA.117.007102.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1267713, encodeId=08dd126e713d1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446299, encodeId=6623144629909, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448233, encodeId=88d214482339a, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480007, encodeId=b0d3148000e7a, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-02-04 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=1267713, encodeId=08dd126e713d1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446299, encodeId=6623144629909, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448233, encodeId=88d214482339a, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480007, encodeId=b0d3148000e7a, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1267713, encodeId=08dd126e713d1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446299, encodeId=6623144629909, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448233, encodeId=88d214482339a, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480007, encodeId=b0d3148000e7a, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1267713, encodeId=08dd126e713d1, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446299, encodeId=6623144629909, content=<a href='/topic/show?id=875e88946d1' target=_blank style='color:#2F92EE;'>#血压控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88946, encryptionId=875e88946d1, topicName=血压控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28a45200046, createdName=gj0733, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448233, encodeId=88d214482339a, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480007, encodeId=b0d3148000e7a, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Sun Feb 04 00:16:00 CST 2018, time=2018-02-04, status=1, ipAttribution=)]

相关资讯

拒绝先入为主:老年人的继发性高血压

75岁男性,有长达30余年的高血压病史,并且有高血压家族史。坚持服用降压药,偶测血压波动于“140~150/80~90mmHg”。但近1个月以来,反复测血压高,波动于“160~170/90~110mmHg”。入院查血钾偏低。

Eur Heart J:高血压患者血压变异性和心血管事件和死亡风险之间相关性分析!

由此可见,无论心血管事件的基线风险如何,随访间收缩压变异性较高与高血压患者心血管事件风险增加有关。并且在年轻患者和收缩压平均值较低的患者中,这种相关性更强。

专家告诉你,治疗高血压的新方法

最近的研究表明,这种叫做肾脏去神经的治疗,平均降压10分,这是一个显著的变化。

高血压伴低血钾 可疑病因众多如何破案?

患者男性,45岁。主诉:体检发现血压高10年,加重4个月。

李玉明:孕期增重与血压调节和糖脂代谢:现状及展望

2016年的统计数据显示,全球18岁以上成年超重人口的数量已超过19亿,其中6.5亿人为肥胖,占世界人口总数的13%。超重和肥胖的流行与久坐不动的生活方式和城市化相关的高脂肪、高能量饮食摄入过量有关。这种趋势在育龄期年轻女性中尤其明显。超重和肥胖是高血压的重要危险因素。据估计,女性中超过50%的新发高血压与超重和肥胖有关。近年来的研究显示,孕期增重过快,不仅与女性产后体质量滞留和超重有关,而且是妊

国家心血管病中心陈伟伟:动态血压监测与高血压管理

高血压是一种最常见的慢性病,也是引发心脑血管疾病最重要的危险因素。据国家心血管病中心发布的《中国心血管病报告2017》显示:目前,中国成人高血压患病率高达25.2%,患者人数达2.7亿,每年与高血压有关的死亡人数达200万,约70%的脑卒中死亡和约50%心肌梗死死亡与高血压密切相关。据《中国居民营养与慢性病状况报告(2015年)》调查显示,我国高血压存在严重的“三低”现象,即“知晓率低、治疗率